10x Genomics
10x Genomics, Inc., founded in 2012 and headquartered in Pleasanton, CA, is a leading life science technology company that builds integrated solutions to interrogate, understand, and master biology. It is widely recognized as a pioneer and market leader in the single-cell analysis field, particularly known for its strong product portfolio supporting transcriptomics, genomics, epigenomes, and spatial transcriptomics. The company’s flagship offering is the Chromium platform, which revolutionized single-cell RNA sequencing (scRNA-seq). The Chromium system utilizes advanced technology to efficiently isolate and barcode thousands of individual cells, a foundational step crucial for modern genomic analysis. This platform supports critical applications such as single-cell RNA, ATAC, and multiome sequencing, enabling researchers to quickly uncover cellular diversity and function at high throughput. By developing innovative and scalable solutions that simplify complex processes, 10x Genomics has significantly advanced biomedical research and precision medicine initiatives globally, solidifying its position at the forefront of single-cell discovery.
Latest Market Research Report on Single Cell Analysis Download PDF Brochure Now
Illumina
Illumina, Inc. is a global technological powerhouse in array-based technologies and DNA sequencing, founded in 1998 and based in San Diego, CA. The company is indispensable to the single-cell analysis market because it provides the essential high-throughput infrastructure required to process the massive sequencing datasets generated by single-cell workflows. Illumina is overwhelmingly the leading provider in the sequencing phase of single-cell research, with its platforms like the NovaSeq and MiSeq series being the industry standard. These systems deliver the required accuracy, scalability, and high throughput necessary for rapidly reading the barcoded nucleic acids derived from thousands of individual cells. Illumina ensures broad utility by continually improving product integration and compatibility with various upstream single-cell preparatory kits from other vendors. By offering comprehensive sequencing instruments, kits, reagents, and robust analysis software, Illumina maintains a transformative impact on both academic genomics research and clinical diagnostics worldwide, making complex genetic analysis feasible and cost-effective.
BD (Becton, Dickinson and Company)
BD (Becton, Dickinson and Company) is a major global medical technology firm, renowned for its innovative solutions across diagnostics, medical supplies, and life sciences. Within single-cell analysis, BD is a leading player, particularly focusing on the crucial pre-sequencing stages of the workflow through its robust genomic tools and advanced flow cytometry systems. BD provides complete solutions that encompass instruments, reagents, and software for cell sorting and sample preparation. The company’s signature product in this area is the BD Rhapsody system, which is essential for conducting research in areas such as immunology, cancer, and infectious diseases. Researchers depend on BD’s systems for reliable isolation and handling of complex tissues and immune cells, ensuring high-quality data generation. By prioritizing reliability, ease of use, and integration within complex biological workflows, BD plays a critical role in providing high-quality starting material and sophisticated cell separation techniques necessary for high-impact single-cell data generation.
Thermo Fisher Scientific
Thermo Fisher Scientific is a globally recognized leader in scientific solutions, offering an extensive and diverse portfolio critical to the life sciences, diagnostics, and analytical instrumentation sectors. The company’s broad presence and technological capabilities make it a fundamental supplier across all stages of single-cell research. Thermo Fisher provides a wide array of products and services specifically for single-cell genomics and proteomics. Key technological platforms, including the Ion Torrent and Applied Biosystems systems, enable researchers to quickly explore cellular heterogeneity and disease mechanisms. Their contributions extend to providing necessary components such as library preparation kits, specialized reagents, and advanced analysis tools that support various single-cell workflows in both research and clinical settings. By continually integrating cutting-edge technology into its high-throughput systems, Thermo Fisher empowers scientists to accelerate the pace of drug discovery, diagnostics development, and fundamental biological research, cementing its role as a key enabler of single-cell discoveries.
Danaher Corporation
Danaher Corporation is a diversified global science and technology conglomerate, which holds a leading position in the single-cell analysis market through its dedicated Life Sciences and Diagnostics segments, featuring subsidiary brands like Beckman Coulter and Leica Microsystems. Danaher focuses on delivering comprehensive, integrated, and automated solutions for complex laboratory workflows, including genomics and molecular diagnostics. The corporation drives the adoption of single-cell technologies by offering tools vital for the preparation and handling of cellular material. Their products include sophisticated tools for cell sorting (flow cytometry), advanced single-cell isolation instruments, and solutions for spatial analysis, which help researchers assess cell location and behavior prior to sequencing. By ensuring high-quality sample preparation and delivering automated systems that produce reliable and reproducible results, Danaher provides the technological foundation necessary for advancing next-generation precision medicine initiatives that rely on granular single-cell insights.
Merck KGaA (MilliporeSigma)
Merck KGaA, which operates as MilliporeSigma in North America, is a global leader in the life sciences sector, providing critical tools, technologies, and high-quality materials essential for research, development, and production. The company is a key supplier in the single-cell analysis ecosystem, supporting cutting-edge research in oncology, genomics, and personalized medicine through its comprehensive portfolio. Merck KGaA is instrumental in providing the innovative tools and high-purity reagents required for single-cell RNA sequencing and proteomics workflows. The reliability and precision of their chemical and biological components are fundamental to the successful execution of sensitive single-cell assays, particularly when dealing with minute sample quantities. By offering advanced reagents and instruments for various omics applications, Merck KGaA ensures researchers can effectively execute complex single-cell experiments, helping to decode cellular diversity and advance the understanding of biological systems and disease mechanisms globally.
QIAGEN
QIAGEN is a leading international provider of sample and assay technologies, offering integrated solutions for molecular diagnostics, applied testing, and academic research. The company plays a significant role in the single-cell genomics market by focusing on optimizing sample and assay preparation, a crucial and often bottlenecked step in single-cell workflows. QIAGEN’s single-cell solutions, notably the QIAGEN QIAseq kits, are widely used for preparing high-quality RNA and DNA samples for sequencing. These products are designed to streamline complex laboratory processes and ensure efficient handling of the scarce material derived from individual cells, maximizing yield and purity. Furthermore, QIAGEN is actively expanding its technological reach, demonstrated by its acquisition of Parse Biosciences, allowing it to offer comprehensive, integrated solutions that cover the entire single-cell pipeline—from sample prep through to sophisticated data analysis. This strategy positions QIAGEN as a crucial facilitator for high-throughput single-cell molecular and immunological testing.
Agilent Technologies
Agilent Technologies, Inc. is a prominent global leader in laboratory systems and analytical instrumentation, known for integrating advanced microfluidics and automation across its platforms. Agilent contributes to single-cell analysis by providing solutions focused on meeting the demand for enhanced reproducibility, higher throughput, and precise sample handling. The company offers specialized microfluidic chips, precision reagents, and consumables for various analytical assays, critical for managing the small fluid volumes in single-cell workflows. A particularly notable contribution is through its Bioanalyzer systems, which utilize microfluidic chips to perform rapid, high-quality analysis and quantification of nucleic acids and proteins derived from single-cell preparations. By developing reliable and high-performance analytical tools, Agilent supports emerging high-growth fields like single-cell genomics, providing researchers with the necessary infrastructure to accelerate their discoveries with accuracy and efficiency.
Mission Bio Inc.
Mission Bio, Inc., founded in 2011, is a life science technology company based in San Francisco, CA, dedicated to applying single-cell biology to advance precision medicine, especially in oncology. The company distinguishes itself by focusing on high-throughput, multi-omics single-cell nucleic acid characterization. Mission Bio’s primary innovation is the Tapestri Platform, which holds the unique distinction of being the first and only single-cell technology to simultaneously detect genetic variations (SNVs, CNVs) and protein data from the same cell. This unparalleled multi-omics capability links genotype and phenotype, which is essential for deeply understanding cellular heterogeneity. The Tapestri Platform is crucial for revealing biomarkers used to stratify patients, predict relapse, and signal treatment resistance in complex diseases like cancer. By enabling researchers to gain detailed insights into individual cell behavior, Mission Bio accelerates the development of advanced, targeted therapies and supports the clinical adoption of precision medicine.
Parse Biosciences
Parse Biosciences is an innovative single-cell technology company, recently acquired by QIAGEN, known for making scalable single-cell sequencing more accessible to the broader research community. The company, based in Seattle, WA, utilizes proprietary split-pool combinatorial barcoding technology, branded as Evercode. This approach eliminates the need for expensive, custom fluidic instruments, thereby simplifying the single-cell RNA sequencing (scRNA-seq) workflow. The Evercode platform is highly versatile, offering kits for Whole Transcriptome (WT), Immune Profiling (TCR/BCR), and fixation solutions, enabling researchers to process significantly more cells and samples simultaneously. Parse Biosciences provides an integrated, end-to-end solution that guides samples from single-cell suspension through library preparation and sequencing, delivering immediate results via its analysis software, Trailmaker. By offering a cost-effective, scalable, and user-friendly platform for large-scale single-cell services, Parse Biosciences is fundamentally accelerating single-cell research and discovery.
Latest Market Research Report on Single Cell Analysis Download PDF Brochure Now